LY2963016 — Competitive Intelligence Brief

LY2963016 (LY2963016) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Basal insulin analog. Area: Diabetes.

phase 3 Basal insulin analog Insulin receptor Diabetes Small molecule

Target snapshot

LY2963016 (LY2963016) — Eli Lilly and Company. LY2963016 is a long-acting basal insulin analog that binds to the insulin receptor to regulate blood glucose by promoting glucose uptake and storage.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
LY2963016 TARGET	LY2963016	Eli Lilly and Company	phase 3	Basal insulin analog	Insulin receptor
Tresiba	INSULIN DEGLUDEC	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2015-01-01
Levemir	INSULIN DETEMIR	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2005-01-01
Apidra	INSULIN GLULISINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2004-01-01
Lantus	INSULIN GLARGINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Novolog	INSULIN ASPART	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Humalog	INSULIN LISPRO	Eli Lilly	marketed	Insulin Analog [EPC]	Insulin receptor	1996-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Basal insulin analog class)

1. Eli Lilly and Company · 4 drugs in this class
2. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 drug in this class
3. Montefiore Medical Center · 1 drug in this class
4. The University of Texas Health Science Center, Houston · 1 drug in this class